NEW YORK, Oct. 1 - Nanogen and Bionomics today said they will work together to develop what they believe will be the world's first molecular-diagnostic test for epilepsy.
Under the terms of the collaboration, the partners will use Nanogen's NanoChip technology together with Bionomics' ionX discovery platform.
Though no financial details were disclosed, the companies agreed that Nanogen would hold exclusive license to any diagnostic-related IP that comes out of the collaboration. In return, Bionomics will be handed funding for research, as well as undisclosed payments for development and commercialization milestones.
Click here for more information.